Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 7, 2009, Pages 674-683

  Wilkinson, Katalin A ^a,b   Seldon, Ronnett ^a   Meintjes, Graeme ^a,c   Rangaka, Molebogeng X ^a   Hanekom, Willem A ^a   Maartens, Gary ^a   Wilkinson, Robert J ^a,b,c,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c GF Jooste Hospital   (South Africa)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bacterial infections; Drug therapy; RNA viruses

Indexed keywords

CD27 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CYTOKINE; GAMMA INTERFERON; LYMPHOCYTE SURFACE MARKER; TUBERCULIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LONGITUDINAL STUDY; MALE; MEMORY CELL; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CYTOKINES; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; IMMUNIZATION; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NEVIRAPINE; STAVUDINE; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 70349439285     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200904-0568OC     Document Type: Article

References (74)

1. Harrison SBR, Ntuli A, editors. South African health review 2007. Durban: Health Systems Trust; 2007.
2. WHO. Global tuberculosis control - surveillance, planning, financing. 2008. Accessed 2008 Dec 28. Available from: http://www.who.int/tb/publications/ global-report/2008/en/.
3. Statistics SA. Mortality and causes of death in South Africa, 1997-2003: findings from death notification. Statistics SA, Private Bag X44, Pretoria 0001 2005.
4. John MA, Menezes CN, Chita G, Sanne I, Grobusch MP. High tuberculosis and HIV coinfection rate, Johannesburg. Emerg Infect Dis 2007;13:795-796.
5. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-824.
6. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-1686. (Pubitemid 28254528)
7. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune JM. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:953-956.
8. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116. (Pubitemid 27450659)
9. Wendland T, Furrer H, Vernazza PL, Frutig K, Christen A, Matter L, Malinverni R, Pichler WJ. Haart in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS 1999;13:1857-1862. (Pubitemid 29509544)
10. Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest 2002;122:597-602. (Pubitemid 35002142)
11. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006;6:280-287.
12. Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne mycobacterium tuberculosis infection in mice. J Exp Med 2001;193:271-280. (Pubitemid 32524511)
13. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to mycobacterium tuberculosis infection. J Exp Med 1993;178:2249-2254. (Pubitemid 23344886)
14. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-740. (Pubitemid 19082507)
15. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR. Tumor necrosis factor-alpha is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 1995;2:561-572.
16. Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003;171:3110-3118. (Pubitemid 37093534)
17. Maartens G, Wilkinson RJ. Tuberculosis. Lancet 2007;370:2030-2043.
18. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Doffinger R, Bernaudin F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432-1435. (Pubitemid 28264836)
19. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, Kabel PJ, Draaisma JM, van Dissel JT, Kroon FP, et al. Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280:1435-1438. (Pubitemid 28264837)
20. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, Levin M. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-1949. (Pubitemid 26428218)
21. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104. (Pubitemid 34940777)
22. Ellner JJ, Hirsch CS, Whalen CC. Correlates of protective immunity to mycobacterium tuberculosis in humans. Clin Infect Dis 2000;30:S279-S282. (Pubitemid 32250422)
23. Hoft DF, Worku S, Kampmann B, Whalen CC, Ellner JJ, Hirsch CS, Brown RB, Larkin R, Li Q, Yun H, et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective mycobacterium tuberculosis immunity. J Infect Dis 2002;186:1448-1457. (Pubitemid 35286112)
24. Reece ST, Kaufmann SH. Rational design of vaccines against tuberculosis directed by basic immunology. Int J Med Microbiol 2008;298:143-150.
25. Fletcher H, McShane H. Tuberculosis vaccines: current status and future prospects. Expert Opin Emerg Drugs 2006;11:207-215. (Pubitemid 43723304)
26. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186:1407-1418. (Pubitemid 27479800)
27. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712. (Pubitemid 129515761)
28. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001;410:106-111. (Pubitemid 32225845)
29. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002;8:379-385. (Pubitemid 34407033)
30. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003;4:835-842. (Pubitemid 37098653)
31. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763. (Pubitemid 38680440)
32. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000;23:75-80.
33. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute siv infection. Nature 2005;434:1093-1097. (Pubitemid 40663481)
34. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, Barton SE, Sudre P, Phillips AN. Infections with mycobacterium tuberculosis and mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. Eurosida study group jd. Am J Respir Crit Care Med 2000;162:865-872.
35. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The adult/adolescent spectrum of HIV disease group. Int J Tuberc Lung Dis 2000;4:1026-1031.
36. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: A cohort study. Lancet 2002;359:2059-2064. (Pubitemid 34680968)
37. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21:1441-1448. (Pubitemid 46988004)
38. Wilkinson KA. Highly active antiretroviral therapy and the restoration of protective responses against tuberculosis in HIV infected people [abstract]. Keystone Symposia: Challenges of Global Vaccine Development. Cape Town, South Africa; 2007.
39. Wilkinson KA. Combined antiretroviral therapy and the restoration of protective responses against tuberculosis in HIV infected people [abstract]. Seventh International Conference on the Pathogenesis of Mycobacterial Infections. Saltsjobaden, Stockholm, Sweden; 2008.
40. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, Callan MF. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003;198:903-911. (Pubitemid 37152927)
41. Amyes E, McMichael AJ, Callan MF. Human CD4+ T cells are predominantly distributed among six phenotypically and functionally distinct subsets. J Immunol 2005;175:5765-5773. (Pubitemid 41508060)
42. Wilkinson KA, Wilkinson RJ, Pathan A, Ewer K, Prakash M, Klenerman P, Maskell N, Davies R, Pasvol G, Lalvani A. Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. Clin Infect Dis 2005;40:184-187. (Pubitemid 40053478)
43. Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, Pasvol G, Wilkinson RJ. Effect of treatment of latent tuberculosis infection on the T cell response to mycobacterium tuberculosis antigens. J Infect Dis 2006;193:354-359. (Pubitemid 43122334)
44. Rangaka MX, Diwakar L, Seldon R, van Cutsem G, Meintjes GA, Morroni C, Mouton P, Shey MS, Maartens G, Wilkinson KA, et al. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis 2007;44:1639-1646. (Pubitemid 46871513)
45. Wilkinson KA, Simsova M, Scholvinck E, Sebo P, Leclerc C, Vordermeier HM, Dickson SJ, Brown JR, Davidson RN, Pasvol G, et al. Efficient ex vivo stimulation of mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids. Infect Immun 2005;73:2991-2998. (Pubitemid 40570368)
46. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 2001;194:1711-1719. (Pubitemid 34028651)
47. Campbell JJ, Murphy KE, Kunkel EJ, Brightling CE, Soler D, Shen Z, Boisvert J, Greenberg HB, Vierra MA, Goodman SB, et al. CCR7 expression and memory T cell diversity in humans. J Immunol 2001;166:877-884. (Pubitemid 32060241)
48. Mackay CR. Dual personality of memory T cells. Nature 1999;401:659-660.
49. Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, Lipsky PE. Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 2005;175:6489-6497. (Pubitemid 41598891)
50. Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ, Hawkridge A, Hussey GD, Maecker H, Kaplan G, et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008;180:3569-3577.
51. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, Ambrozak DR, Precopio ML, Scheinberg P, Alder NC, et al. Immunisation with BCG and recombinant MVA85a induces longlasting, polyfunctional mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007;37:3089-3100. (Pubitemid 350131288)
52. Hanekom WA. The immune response to BCG vaccination of newborns. Ann N Y Acad Sci 2005;1062:69-78.
53. Evans TG, Bonnez W, Soucier HR, Fitzgerald T, Gibbons DC, Reichman RC. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Antiviral Res 1998;39:163-173. (Pubitemid 28495572)
54. Amendola A, Poccia F, Martini F, Gioia C, Galati V, Pierdominici M, Marziali M, Pandolfi F, Colizzi V, Piacentini M, et al. Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan study group. Clin Exp Immunol 2000;120:324-332.
55. Landay AL, Bettendorf D, Chan E, Spritzler J, Schmitz JL, Bucy RP, Gonzalez CJ, Schnizlein-Bick CT, Evans T, Squires KE, et al. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses 2002;18:95-102. (Pubitemid 34161228)
56. Lange CG, Lederman MM, Madero JS, Medvik K, Asaad R, Pacheko C, Carranza C, Valdez H. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr 2002;30:33-40. (Pubitemid 34506685)
57. Mussini C, Pinti M, Borghi V, Nasi M, Amorico G, Monterastelli E, Moretti L, Troiano L, Esposito R, Cossarizza A. Features of "CD4-exploders," HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS 2002;16:1609-1616.
58. Pontesilli O, Kerkhof-Garde S, Pakker NG, Notermans DW, Roos MT, Klein MR, Danner SA, Miedema F. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol Lett 1999;66:213-217. (Pubitemid 29136841)
59. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. Rapid effector function in CD8+ memory T cells. J Exp Med 1997;186:859-865. (Pubitemid 27407347)
60. Sutherland R, Yang H, Scriba TJ, Ondondo B, Robinson N, Conlon C, Suttill A, McShane H, Fidler S, McMichael A, et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006;20:821-829. (Pubitemid 43731563)
61. Mendonca M, Tanji MM, Silva LC, Silveira GG, Oliveira SC, Duarte AJ, Benard G. Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease. Clin Immunol 2007;125:60-66. (Pubitemid 47376923)
62. Lawn SD, Wood R. Tuberculosis control in South Africa - will HAART help? S Afr Med J 2006;96:502-504.
63. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-2116. (Pubitemid 41668999)
64. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev 1997;157:61-72.
65. Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, Meenhorst PL, Goudsmit J, Roos MT, Schellekens PT, Miedema F, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999;180:1050-1056. (Pubitemid 30070186)
66. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-695. (Pubitemid 29003949)
67. Ribeiro RM, de Boer RJ. The contribution of the thymus to the recovery of peripheral naive T-cell numbers during antiretroviral treatment for HIV infection. J Acquir Immune Defic Syndr 2008;49:1-8.
68. Kaufmann GR, Zaunders J, Murray J, Kelleher AD, Lewin SR, Solomon A, Smith D, Cooper DA. Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling. AIDS Res Hum Retroviruses 2001;17:147-159. (Pubitemid 32099299)
69. Connell TG, Shey MS, Seldon R, Rangaka MX, van Cutsem G, Simsova M, Marcekova Z, Sebo P, Curtis N, Diwakar L, et al. Enhanced ex vivo stimulation of mycobacterium tuberculosis-specific T cells in HIV-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector. Clin Vaccine Immunol 2007;14:847-854.
70. Rangaka MX, Wilkinson KA, Seldon R, Van Cutsem G, Meintjes GA, Morroni C, Mouton P, Diwakar L, Connell TG, Maartens G, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007;175:514-520. (Pubitemid 46354256)
71. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001;167:5217-5225. (Pubitemid 33009758)
72. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009;17:183-188.
73. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, Mex P, Miekley D, Kaufmann SH. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci USA 2007;104:12434-12439. (Pubitemid 47206155)
74. Day CL, Mkhwanazi N, Reddy S, Mncube Z, van der Stok M, Klenerman P, Walker BD. Detection of polyfunctional mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis 2008;197:990-999. (Pubitemid 351590027)